TCGA-05-5423-01A-01R-1628-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.450
- ALLOGRAFT_REJECTION+0.380
- INTERFERON_ALPHA_RESPONSE+0.370
- BILE_ACID_METABOLISM+0.360
- FATTY_ACID_METABOLISM+0.350
- INTERFERON_GAMMA_RESPONSE+0.330
- INFLAMMATORY_RESPONSE+0.300
- PEROXISOME+0.270
- ADIPOGENESIS+0.230
- KRAS_SIGNALING_UP+0.220
Top 10 suppressed
- G2M_CHECKPOINT-0.560
- MITOTIC_SPINDLE-0.540
- WNT_BETA_CATENIN_SIGNALING-0.530
- HEDGEHOG_SIGNALING-0.460
- E2F_TARGETS-0.450
- APICAL_SURFACE-0.410
- MYC_TARGETS_V2-0.410
- TGF_BETA_SIGNALING-0.330
- UV_RESPONSE_DN-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5068-01A-01R-1628-07 | — | cohortA1 | 0.927 |
| 2 | TCGA-67-3770-01A-01R-0946-07 | — | cohortA1 | 0.917 |
| 3 | TCGA-67-3773-01A-01R-0946-07 | — | cohortA1 | 0.877 |
| 4 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.853 |
| 5 | da7cbc0a-95dc-4303-a5dd-75857c066f3b | — | — | 0.839 |
| 6 | TCGA-05-5420-01A-01R-1628-07 | — | cohortA1 | 0.837 |
| 7 | TCGA-OR-A5J6-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.832 |
| 8 | ERR2598330 | fetal | fetal | 0.831 |
| 9 | SRR33532817 | — | D | 0.820 |
| 10 | TCGA-5N-A9KM-01A-11R-A42T-07 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |